| Literature DB >> 32778073 |
Makoto Takeuchi1, Michiaki Nagai2, Keigo Dote1, Masaya Kato1, Noboru Oda1, Eiji Kunita1, Eisuke Kagawa1, Aya Yamane1, Yusuke Kobayashi1, Haruko Shiota1, Ayano Osawa1, Hiroshi Kobatake1.
Abstract
BACKGROUND: Regardless of patients' baseline renal function, worsening renal function (WRF) during hospitalization is associated with poor outcomes. In individuals with acute heart failure (AHF), one predictor of WRF is an early drop in systolic blood pressure (SBP). Few studies have investigated WRF in elderly AHF patients or the influence of these patients' heart rate (HR) at admission on the relationship between an early SBP drop SBP and the AHF.Entities:
Keywords: Acute heart failure; Early drop in systolic blood pressure; Elderly; Heart rate; Worsening renal function
Mesh:
Year: 2020 PMID: 32778073 PMCID: PMC7419179 DOI: 10.1186/s12872-020-01656-1
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1Study sample inclusion and exclusion flow chart
Baseline characteristics of the elderly acute heart failure patients with and without worsening renal function
| Baseline characteristics | Total ( | ||
|---|---|---|---|
| WRF | |||
| Yes (n = 36) | No ( | ||
| Age, yrs | 82.9 ± 6.0 | 82.3 ± 6.4 | 83.1 ± 6.0 |
| Male, % | 49.4 | 41.7 | 50.7 |
| Body weight at assessment, kg | 50.1 ± 12.0 | 48.4 ± 14.3 | 50.5 ± 11.5 |
| Clinical scenario 1, % | 41.2 | 58.3* | 38.3 |
| Clinical scenario 2, % | 30.6 | 16.7* | 33.0 |
| Clinical scenario 3, % | 8.2 | 8.3 | 8.1 |
| Clinical scenario 4, % | 13.1 | 13.9 | 12.4 |
| Ejection fraction, % | 45.6 ± 14.7 | 42.5 ± 13.0 | 46.2 ± 14.9 |
| Current smoking, % | 25.3 | 27.8 | 24.9 |
| Daily alcohol intake, % | 20.4 | 11.1 | 22.0 |
| Hypertension, % | 78.3 | 91.7* | 76.0 |
| Diabetes mellitus, % | 33.9 | 33.3 | 34.0 |
| Lipid disorder, % | 44.4 | 44.4 | 38.8 |
| Chronic atrial fibrillation, % | 23.6 | 22.2 | 23.9 |
| Baseline laboratory values: | |||
| Log BNP | 6.07 ± 1.2 | 6.38 ± 0.9 | 6.01 ± 1.2 |
| Hemoglobin, g/dL | 11.8 ± 2.1 | 11.7 ± 2.2 | 11.8 ± 2.1 |
| BUN, mg/dL | 31.5 ± 17.3 | 30.7 ± 16.5 | 31.6 ± 17.5 |
| Serum creatinine, g/dL | 1.50 ± 1.0 | 1.61 ± 1.0 | 1.47 ± 1.0 |
| Medication at baseline: | |||
| ACEI use, % | 8.17 | 2.78 | 9.1 |
| ARB use, % | 45.3 | 52.8 | 44.0 |
| CCB use, % | 40.0 | 36.1 | 40.7 |
| Beta-blocker, % | 29.0 | 36.1 | 27.8 |
| Loop diuretics, % | 50.0 | 58.3 | 48.6 |
| Medication during admission: | |||
| I.V. loop diuretic use, % | 75.5 | 88.9* | 73.2 |
| I.V. isosorbide dinitrate, % | 27.8 | 50.0** | 23.9 |
| I.V. carperitide use, % | 7.8 | 5.6 | 8.1 |
| Blood pressure and heart rate parameters: | |||
| Systolic blood pressure admission, mmHg | 140 ± 32 | 158 ± 37*** | 137 ± 30 |
| Diastolic blood pressure at admission, mmHg | 76.5 ± 19 | 78.5 ± 18 | 76.1 ± 20 |
| Heart rate at admission, mmHg | 88.1 ± 28 | 79.3 ± 21* | 89.6 ± 29 |
| Early systolic blood pressure drop, mmHg | 35.3 ± 31 | 51.3 ± 30*** | 32.5 ± 30 |
Data are mean ± standard deviation or as percentages. Analysis of variance for continuous variables and the χ2 test for qualitative variables were used.*p < 0.05, **p < 0.01, ***p < 0.001 compared to the no-worsening renal function group. BNP indicates B-type natriuretic peptide; BUN, blood urea nitrogen; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; I.V., intravenous; WRF, worsening renal function
Univariate logistic regression analysis between early systolic blood pressure drop and worsening renal function
| Baseline characteristics | Odds ratio | 95% CI | |
|---|---|---|---|
| Age, yrs | 0.98 | 0.92–1.04 | 0.5 |
| Male, yes = 1, no = 0 | 0.69 | 0.34–1.42 | 0.3 |
| Body weight at assessment, kg | 0.99 | 0.96–1.02 | 0.4 |
| Clinical scenario 1, yes = 1, no = 0 | 1.42 | 0.64–3.18 | 0.4 |
| Clinical scenario 2, yes = 1, no = 0 | 1 (Ref.) | – | – |
| Clinical scenario 3, yes = 1, no = 0 | 1.04 | 0.27–3.99 | 0.96 |
| Clinical scenario 4, yes = 1, no = 0 | 1.33 | 0.43–4.08 | 0.6 |
| Ejection fraction, % | 0.18 | 0.96–1.01 | 0.2 |
| Current smoking, yes = 1, no = 0 | 1.16 | 0.53–2.57 | 0.7 |
| Daily alcohol intake, yes = 1, no = 0 | 0.14 | 0.15–1.32 | 0.1 |
| Hypertension, yes = 1, no = 0 | 3.48 | 1.02–11.8 | 0.046 |
| Diabetes mellitus, yes = 1, no = 0 | 0.97 | 0.46–2.06 | 0.9 |
| Lipid disorder, yes = 1, no = 0 | 1.23 | 0.62–2.58 | 0.5 |
| Chronic atrial fibrillation, yes = 1, no = 0 | 0.91 | 0.39–2.12 | 0.8 |
| Baseline laboratory values: | |||
| Log BNP | 1.36 | 0.97–1.91 | 0.08 |
| Hemoglobin, g/dL | 0.97 | 0.82–1.15 | 0.7 |
| BUN, mg/dL | 0.997 | 0.98–1.02 | 0.8 |
| Serum creatinine, g/dL | 1.12 | 0.83–1.53 | 0.5 |
| Medication at baseline: | |||
| ACEI use, yes = 1, no = 0 | 0.29 | 0.04–2.20 | 0.2 |
| ARB use, yes = 1, no = 0 | 1.42 | 0.70–2.89 | 0.3 |
| CCB use, yes = 1, no = 0 | 0.83 | 0.40–1.72 | 0.6 |
| Beta-blocker, yes = 1, no = 0 | 1.47 | 0.70–3.01 | 0.3 |
| Loop diuretics, yes = 1, no = 0 | 1.48 | 0.73–3.04 | 0.3 |
| Medication during admission | |||
| I.V. loop diuretic use, yes = 1, no = 0 | 2.93 | 0.99–8.65 | 0.052 |
| I.V. isosorbide dinitrate, yes = 1, no = 0 | 3.18 | 1.54–6.58 | 0.002 |
| I.V. carperitide use, yes = 1, no = 0 | 0.66 | 0.15–3.01 | 0.6 |
| Blood pressure and heart rate parameters | |||
| Systolic blood pressure at admission, mmHg | 1.02 | 1.01–1.03 | 0.001 |
| Diastolic blood pressure at admission, mmHg | 1.01 | 0.99–1.03 | 0.5 |
| Heart rate at admission, mmHg | 0.987 | 0.97–0.999 | 0.046 |
| Early systolic blood pressure drop, mmHg | 1.02 | 1.01–1.03 | 0.001 |
Each parameters was included to the simple logistic regression model for worsening renal function. Patients with clinical scenario 2 were the reference (Ref.) group. BNP indicates B-type natriuretic peptide; BUN, blood urea nitrogen; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; I.V., intravenous
Logistic regression model of early systolic blood pressure drop for subsequential worsening renal function
| Trait | Adjusted odds ratio | 95% CI | |
|---|---|---|---|
| Age, yrs | 0.95 | 0.88–1.02 | 0.13 |
| Male, yes = 1, no = 0 | 0.54 | 0.22–1.33 | 0.18 |
| Ejection fraction, % | 0.97 | 0.94–1.01 | 0.09 |
| Hypertension, yes = 1, no = 0 | 2.93 | 0.77–11.1 | 0.12 |
| Beta-blocker at baseline, yes = 1, no = 0 | 1.44 | 0.60–3.44 | 0.41 |
| Log BNP | 1.05 | 0.65–1.70 | 0.85 |
| I.V. loop diuretic use during admission, yes = 1, no = 0 | 2.21 | 0.58–8.35 | 0.24 |
| I.V. isosorbide dinitrate during admission, yes = 1, no = 0 | 1.80 | 0.73–4.48 | 0.20 |
| I.V. carperitide use during admission, yes = 1, no = 0 | 0.68 | 0.13–3.57 | 0.65 |
| Heart rate at admission, bpm | 0.98 | 0.96–0.99 | 0.004 |
| Early systolic blood pressure drop, mmHg | 1.02 | 1.004–1.03 | 0.02 |
Parameter were added simultaneously to the regression model. BNP indicates B-type natriuretic peptide; I.V., intravenous